Key result
New oral antiplatelet agents, including prasugrel and ticagrelor, demonstrate higher efficacy and reduced rates of vascular death, myocardial infarction, or stroke compared with clopidogrel.
Why the study?
Do new oral antiplatelet agents (prasugrel and ticagrelor) improve clinical outcomes compared to clopidogrel in patients with acute coronary syndrome?
Do new oral antiplatelet agents (prasugrel and ticagrelor) improve clinical outcomes compared to clopidogrel in patients with acute coronary syndrome?
Newer P2Y12 inhibitors like prasugrel and ticagrelor offer improved efficacy and more consistent platelet inhibition compared to clopidogrel in patients with acute coronary syndrome.
May support prasugrel or ticagrelor preference in ACS; leaves open bleeding trade-offs and real-world applicability.
Antiplatelet agents play an essential role in the treatment of acute coronary syndrome (ACS). Aspirin and thienopyridines comprise the major classes of antiplatelet therapies demonstrated to be of benefit in the treatment of ACS. Thienopyridines are a class of drugs that function via inhibition of the adenosine diphosphate (ADP) P2Y12 platelet receptors. While clopidogrel remains in extensive use in clinical practice, it cannot meet the needs in many clinical conditions because of its pharmacological limitations. In recent years, newly developed P2Y12 antagonists, such as prasugrel and ticagrelor, have proven to be of higher efficacy and less resistance. As a third generation thienopyridine, prasugrel exerts a much more rapid and consistent inhibitory effect on platelet aggregation than clopidogrel. Treatment with ticagrelor, nonthienopyridine oral antiplatelet drug, significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding as compared with clopidogrel. The present review aims to discuss the current knowledge on the safety and efficacy of new oral antiplatelet agents including prasugrel and ticagrelor. (Korean J Med 2013;85:10-14)
No takes yet. Share an insight, caveat, or question.
Kang et al. (2013) conducted a review in Acute Coronary Syndrome. New oral antiplatelet agents (prasugrel and ticagrelor) vs. Clopidogrel was evaluated. New oral antiplatelet agents, including prasugrel and ticagrelor, demonstrate higher efficacy and reduced rates of vascular death, myocardial infarction, or stroke compared with clopidogrel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: